This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Idera Pharmaceuticals Presents Data In Preclinical Models Of Lymphoma On IMO-4200, A Dual Agonist Of TLRs 7 And 8, At The American Society For Hematology Meeting

Idera Pharmaceuticals (Nasdaq: IDRA) today announced that it presented new data showing that IMO-4200, a dual agonist of Toll-like receptor (TLR) 7 and TLR8, in combination with approved cancer treatments increased antitumor activity in preclinical models of lymphoma. The presentation by Idera scientists, entitled “IMO-4200, a novel TLR7 and TLR8 dual agonist, enhances antitumor effect of ofatumumab, rituximab and cytotoxics in preclinical models of hematological malignancies”, abstract number 3724, was made at the 53 rd annual meeting of the American Society for Hematology being held in San Diego, California December 11-13, 2011.

“The data presented show that IMO-4200 provides a novel scientific rationale for the targeted immunotherapy of hematological malignancies,” said Nicola La Monica, Ph.D., VP of Biology of Idera Pharmaceuticals. “IMO-4200 has shown to potentiate the anti-cancer activity of a broad range of approved agents, including rituximab, bortezomib and ofatumumab, in preclinical models of lymphoma.”

In the data presented today, IMO-4200 was evaluated in preclinical cell-based assays and in combination with approved cancer therapy agents in mouse models of lymphoma.
  • IMO-4200 in combination with ofatumumab, an anti-CD20 antibody, resulted in:
    • improved antitumor activity
    • increased survival compared to treatment with either agent alone
    • enhancement of complement-dependent cytotoxicity, a mechanism by which ofatumumab exerts its antitumor effect
  • IMO-4200 in combination with rituximab, an anti-CD20 antibody, and fludarabine or IMO-4200 in combination with rituximab and bendamustine resulted in:
    • improved antitumor activity
    • increased survival
    • enhanced clearance of circulating tumor cells
    • greater antibody-dependent cell cytotoxicity, a mechanism by which rituximab exerts its effect

Authors of the presentation were Daqing Wang, Ph.D., Melissa Precopio, Ph.D., Michael J. Reardon, Ph.D., Tao Lan Ph.D., Jimmy X. Tang, Ekambar R. Kandimalla, Ph.D., Alice Bexon M.D., Nicola La Monica, Ph.D. and Sudhir Agrawal, D. Phil.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs